UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

LIQUID BIOPSY OF BILE IN PATIENTS WITH PANCREATIC DUCTAL ADENOCARCINOMA: PRELIMINARY RESULTS FROM THE "BILE BIOPSY" STUDY

Cecilia Binda 1, Paolo Giuffrida 1, Michele Zanoni 2, Giorgia Marisi 2, Andrea Fabbri 1, Chiara Coluccio 1, Stefano Fabbri 1, Barbara Perini 3, Monica Cricca 4, Vittorio Sambri 4, Paola Ulivi 2, Carlo Fabbri 1

Affiliations

1 AUSL Romagna, Forlì, Italy

2 IRCCS, Istituto Romagnolo per lo studio dei Tumori (IRST), Meldola (FC), Italy

3 Azienda Ospedale-Università di Padova (AOUP), Padova, Italy

4 University of Bologna, Bologna, Italy

Summary

AI Generated

A prospective study of 46 pancreatic ductal adenocarcinoma patients demonstrates that bile contains significantly higher circulating tumor DNA concentrations than plasma and correlates with disease stage.

Bile cfDNA concentrations were significantly higher than plasma (mean 49 ng/uL versus 3.3 ng/uL, p=0.001) in patients undergoing biliary drainage for PDAC-associated obstructive jaundice.
Bile cfDNA levels correlated with disease stage, showing higher concentrations in metastatic patients (81 ng/uL) compared to locally advanced (22 ng/uL) or resectable cases (55 ng/uL).
Plasma cfDNA levels showed no significant correlation with tumor stage (p=0.94).
Survival analyses showed a non-significant correlation between bile cfDNA concentrations and patient prognosis (Spearman coefficient -0.23, p=0.2).
The authors state that further analyses including genetic sequencing and larger cohort validation are needed to establish clinical utility of bile-derived biomarkers.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

With a 5-year survival rate of about 10%, pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers in the world. Even among diseases of similar stages, patients' responses to chemotherapy vary greatly, as evidenced by the stark differences in short and median overall survival. Liquid biopsy has emerged as a promising tool for non-invasive tumor profiling, but its application in bile has not been extensively studied. Given the direct contact of bile with pancreatic and biliary malignancies, bile could represent an important substrate for tumor biomarkers and may provide diagnostic and prognostic insights. This study aimed to evaluate the feasibility of circulating tumor DNA (ctDNA) extraction from the bile.

Aims & Methods

A prospective observational study was conducted on patients with PDAC-associated obstructive jaundice undergoing endoscopic or percutaneous biliary drainage. Bile samples were collected during the procedure, alongside plasma and tissue biopsies obtained via EUS-guided fine-needle biopsy (EUS-FNB) or intraductal biopsies. DNA extraction and next-generation sequencing (NGS) were performed to analyze genetic alterations. Clinical data, including tumor stage, treatment response, and survival outcomes, were recorded. Statistical analyses were conducted using Stata 15, with significance set at p<0.05. The primary endpoint was to compare cfDNA extracted from bile with that from plasma and tumor tissue. Secondary outcomes included assessing the prognostic value of bile cfDNA and its correlation with disease progression and treatment response.

Results

A total of 46 patients with an histological diagnosis of PDAC were included in the preliminary analysis. The mean tumor size was 35 mm (SD 13,1), and 39% of patients had metastatic disease at diagnosis. Biliary drainage was performed by endoscopic retrograde cholangiopancreatography (ERCP) in 60.9% of cases, EUS-guided drainage in 32%, and percutaneous drainage in 7,1%.
Quantitative analysis revealed significantly higher cfDNA concentrations in bile (mean 49 ng/uL) compared to plasma (mean 3,3 ng/uL, p=0.001) Figure 1. cfDNA levels in bile correlated with disease stage, showing higher concentrations in metastatic patients (mean 81 ng/uL) than in locally advanced (22 ng/uL) or resectable cases (55ng/uL). On the contrary, no significant correlation was found between plasma cfDNA levels and tumor stage (p=0.94). At three-month follow-up, 25.9% of patients showed disease progression, while 48.2% had stable disease, and 11.1% achieved complete remission. Survival analyses suggested a non-significant correlation between bile cfDNA concentrations and patient’s prognosis (Spearman coefficient -0.23, p=0.2).

Conclusion

These preliminary findings demonstrate the feasibility and a potential role of bile liquid biopsy in PDAC patients. Bile showed significantly higher concentrations of cfDNA than plasma cfDNA and representing a promising substrate for future tumor analysis and for a deeper comprehension of patient’s prognosis. Further analyses, including genetic sequencing and larger cohort validation, are warranted to establish the clinical utility of bile-derived biomarkers in guiding personalized therapeutic strategies for PDAC patients.

Conference

UEG Week Berlin 2025

Topics

Pancreas

Submission format

Abstract

Session

Pancreatic cancer: Treatment and outcomes (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Dilated main pancreatic duct of unknown origin: Chronic pancreatitis or MD-IPMN?

Alexander Arlt

Early colorectal cancer: Strategy after excision - surgeon and endoscopist

Leon M.G. Moons

Robotic living donor hepatectomy: A novel tool to expand the donor pool

Moritz Schmelzle

DEVELOPMENT AND VALIDATION OF A NOVEL PATIENT-REPORTED OUTCOME FOR MICROSCOPIC COLITIS – MICROSCOPIC COLITIS SCORE (MCS)

Henrik Hjortswang

COMPARABLE OUTCOMES AFTER EUS-GUIDED GASTROENTEROSTOMY IN PATIENTS WITH VERSUS WITHOUT ABDOMINAL CARCINOMATOSIS: A SINGLE CENTRE STUDY

Francesco Di Matteo

Persistent lipase and localised damage: Cause or consequence?

Peter Hegyi

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Dilated main pancreatic duct of unknown origin: Chronic pancreatitis or MD-IPMN?

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.